SurGraft XT® is a dual layer amnion derived allograft
INTENDED USES: Intended for the treatment of non-healing wounds and burn injuries. SurGraft is directed for use in patients with acute or chronic wounds, including but not limited to, chronic, non-infected, diabetic foot ulcers, chronic, non-infected, partial or full-thickness diabetic foot skin ulcers (due to venous insufficiency), pressure ulcer, surgical wounds and burns which have not adequately responded to conventional therapy.
CLAIMED BENEFITS: The membrane sheet provides a protective covering that may aid in wound management; The amniotic membrane has unique non-immunological properties; The extracellular matrix acts as a scaffolding and may potentiate the migration and adhesion of resident cells; The membrane is a natural source of cytokines and growth factors. SurGraft is minimally manipulated Human Cell Tissue Product (HCT/P) intended for homologous use.
OPTIONS: Per Square Centimeter
An invitation to view this topic will be emailed to specified recipients.
Sorry, this content is only available to registered members. Please register for FREE account to gain access.
To access this premium feature and more, upgrade to a premium plan today. Or browse to enjoy free content and tools.
WoundReference is a clinical decision support platform for experienced and new wound care clinicians at the point-of-care